Tag Archives | ADC antibody-drug conjugates

What Sell-Off? Biotechs Cruise: CLVS, SGEN

Stocks in Sharp Sell-Off on Potential FED Rate Increase and Strong Dollar Deflation is Still Lurking S&P Down 1.7%, NASDAQ down 1.67% Biotech stocks avoided the severe sell-off today apparently immune to the strong dollar, flat earnings growth and FED interest rate concerns. Although life science stocks were mixed the bellwether ETFs held their ground: […]

Continue Reading

Rayno Biopharmaceutical Portfolio Performance: Sector is up 80% from 7/1/13 to 2/11/15

Biotech Stocks Up YTD Despite Choppy Tape NASDAQ 4857.61 approaching March 10, 2000 high of 5048.62 IBB at 320.42 up 5.63% YTD and 351% over 10 Years We have updated our post from 7/1/13 on the Rayno Biopharmaceutical Portfolio with re-balancing.  We are approaching all time highs touched in late January 2015. The life science portfolios […]

Continue Reading

JPMorgan Conference Notes #2: Biotech Stocks Surge to New Highs Then Sell Off on Energy/Materials Weakness

FBT up 2.4% to $108 then drifts back to 107; NASDAQ flat 4661 DOW bounced around in 425 point range. Mixed market among biotech stocks after NASDAQ  and S&P sell off; momentum eases. Mid-cap immuno-oncology stocks : down AGIO, BLUE, EPZM, SGEN.; up CLVS, INCY, MDVN. Rayno Life Science Movers: Pharmacyclics (PCYC) up 16% to […]

Continue Reading

Happy New Year 2015!

Wishing you all a Happy and Prosperous New Year! Biotech stocks were up 47% in 2014. In 2014 the first quarter was the most volatile. Sign up now to receive all of our market and portfolio updates. In December we posted updates on our Rayno Life Science Portfolios: Rayno Diagnostics and Tools Part 2: Rayno […]

Continue Reading

Rayno Life Science Stocks: Up 30%+ YTD After A Volatile October

Investors Whipsawed By V-Shaped Rally NASDAQ at New Highs 4631 DOW at New Highs 17,390 Investors got what was forecasted-a volatile October that moved from fear to greed in two weeks! The market was buffeted by the Ebola scare, macro analysts decrying easy money from the FED and a potential global economic slowdown. But fears […]

Continue Reading